ECOG-ACRIN Network Group Operations Center

ECOG-ACRIN 网络集团运营中心

• 批准号: 10359815
• 负责人: Peter J ODwyer
• 金额: $ 1192.63万
• 依托单位: ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-29 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10359815
• 关键词: Adolescent and Young Adult; Adult; Affect; American College of Radiology Imaging Network; Automobile Driving; Bioinformatics; Biological; Biological Assay; Biological Markers; Biometry; Cancer Biology; Cancer Center; Cancer Patient; Cancer Research Network; Cancer Therapy Evaluation Program; Caring; Center for Translational Science Activities; Clinical Markers; Clinical Research; Clinical Trials; Clinical Trials Network; Collaborations; Communities; Community Clinical Oncology Program; Community Practice; Complex; Dana-Farber Cancer Institute; Data; Data Analyses; Databases; Development; Diagnostic Imaging; Discipline; Disease; Early Diagnosis; Eastern Cooperative Oncology Group; Effectiveness; Environment; Evolution; Fostering; Foundations; Funding; Future; Goals; Image; Immunologics; Immunology; Infrastructure; Institutes; International; Intervention; Investigational Therapies; Laboratories; Lead; Leadership; Life; Malignant Neoplasms; Mentorship; Modeling; Monitor; National Clinical Trials Network; Oncology; Outcomes Research; Participant; Patient Outcomes Assessments; Patient Participation; Patients; Phase II Clinical Trials; Phase III Clinical Trials; Pilot Projects; Population; Positioning Attribute; Prevalence; Public Health; Reporting; Research; Research Personnel; Resources; Risk; Science; Scientist; Site; Specialized Program of Research Excellence; System; Therapeutic; Tissue Banks; Translating; Universities; advanced disease; advocacy organizations; anticancer research; base; biobank; biomarker-driven; cancer clinical trial; cancer therapy; cancer type; care outcomes; career development; comparative effectiveness; data management; data repository; effectiveness outcome; experience; image archival system; imaging study; improved; improved outcome; innovation; member; molecular imaging; multidisciplinary; multimodality; next generation; novel; operation; programs; quantitative imaging; scientific organization; screening; standard of care; treatment effect

Overall: Publicly-funded cancer clinical trials continue to establish new standards of care and improve outcomes for cancer patients. ECOG-ACRIN (EA) has instituted an organizational matrix based on the integration of biological and imaging studies with clinical trials of novel anti-cancer therapies to conduct cutting-edge clinical research and promote scientific discovery. We have incorporated expertise in imaging, cancer biology and therapy within our scientific organization, working closely with the biostatistics and data management centers at the Dana Farber Cancer Institute and Brown University, to propose a research plan that recognizes the importance of biomarkers to bring precisely targeted clinical trials to broad populations of cancer patients. The EA biorepositories, image databases, immunological laboratories, and associated translational science centers will bring together the correlative science studies that relate cancer biology to clinical markers of treatment effect in a data-rich environment. EA embraces the goals and spirit of the NCTN to conduct science-driven clinical trials to improve the lives of adults with cancer. EA clinical trials are implemented through an efficient operational infrastructure that enables access to cutting-edge treatments across the US from large cancer centers to community practices and assures accrual to complex trials in cancers of varying prevalence. Our science is driven by our membership, which includes the NCI-funded Cancer Centers, the Specialized Programs of Research Excellence (SPOREs), the ETCTN (Experimental Therapeutics Clinical Trials Network), the Quantitative Imaging Network (QIN), the NCTN Lead Academic Participating Sites (LAPS), and the National Community Oncology Research Programs (NCORP). As committed participants in the NCTN and in all aspects of CTEP-led cancer research, EA collaborates across the system to promote and advance the collective efforts of all of the groups. We make available the mentorship and opportunity needed to nourish the next generation of investigators. EA is positioned to make unique contributions to the NCTN, working to translate NCI-supported science into improved outcomes for cancer patients. This model, together with developing innovation in large data analysis, will yield high quality trials that have the potential to be practice-changing, applicable to both academic and community environments, and providing imaging and other biomarkers to identify patients who benefit most.

全面的： 由公共资助的癌症临床试验继续建立新的护理标准并改善 癌症患者的结果。 Ecog-acrin（EA）建立了基于组织矩阵的 关于生物学和成像研究与新抗癌的临床试验的整合 进行尖端临床研究并促进科学发现的疗法。我们有 在我们的科学组织内部成像，癌症生物学和治疗方面的专业知识， 与Dana Farber癌的生物统计学和数据管理中心紧密合作 研究所和布朗大学，提出一项研究计划，以认识 生物标志物将精确靶向临床试验带到广泛的癌症患者中。这 EA生物剂，图像数据库，免疫实验室和相关翻译 科学中心将汇集将癌症生物学与 在数据丰富的环境中，治疗效果的临床标记。 EA拥抱目标和精神 NCTN进行以科学为导向的临床试验，以改善成人癌症的生活。 EA临床试验是通过有效的运营基础设施实施的 从大型癌症中心到社区，可以进入整个美国的尖端治疗 实践和确保在不同患病率的癌症中进行复杂试验的应计。我们的科学 由我们的会员资格驱动，包括NCI资助的癌症中心，专业 卓越研究计划（孢子），ETCTN（实验治疗学临床 试验网络），定量成像网络（QIN），NCTN领导学术参与 地点（圈）和民族社区肿瘤研究计划（NCORP）。作为 在NCTN和CTEP领导的癌症研究的各个方面的参与者，EA 在整个系统中进行合作，以促进和推进所有小组的集体努力。 我们提供了滋养下一代所需的指导和机会 调查人员。 EA可以为NCTN做出独特的贡献，努力翻译 NCI支持的科学改善了癌症患者的结果。这个模型，以及 在大型数据分析中开发创新，将产生具有潜力的高质量试验 改变练习，适用于学术和社区环境，并提供 成像和其他生物标志物，以识别受益最大的患者。